{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:19:06Z","timestamp":1790659146737,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1684\/bdc.2011.1404","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:58:33Z","timestamp":1565726313000},"page":"879-887","source":"Crossref","is-referenced-by-count":2,"title":["IMiD en h\u00e9matologie"],"prefix":"10.1016","volume":"98","author":[{"given":"Mathieu","family":"W\u00e9meau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1404_bib0005","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1684\/bdc.2011.1404_bib0010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/168.2.408","article-title":"The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum","volume":"168","author":"Sampaio","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1684\/bdc.2011.1404_bib0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cellimm.2004.09.003","article-title":"Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner","volume":"230","author":"Payvandi","year":"2004","journal-title":"Cell Immunol"},{"key":"10.1684\/bdc.2011.1404_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656560802627903","article-title":"Lenalidomide: a novel anticancer drug with multiple modalities","volume":"10","author":"Galustian","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1684\/bdc.2011.1404_bib0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1684\/bdc.2011.1404_bib0030","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","article-title":"Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity","volume":"168","author":"Dredge","year":"2002","journal-title":"J Immunol"},{"key":"10.1684\/bdc.2011.1404_bib0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1684\/bdc.2011.1404_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1684\/bdc.2011.1404_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiD) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2011.1404_bib0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0055","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2011.1404_bib0060","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1404_bib0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.thj.6200031","article-title":"Thalidomide in patients with advanced multiple myeloma","volume":"1","author":"Yakoub-Agha","year":"2000","journal-title":"Hematol J"},{"key":"10.1684\/bdc.2011.1404_bib0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bmt.1704756","article-title":"Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the intergroupe francophone du myelome (IFM) and the societ\u00e9 fran\u00e7aise de greffe de moelle et th\u00e9rapie cellulaire (SFGM-TC)","volume":"35","author":"Mohty","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1684\/bdc.2011.1404_bib0075","first-page":"101","article-title":"Treatment of multiple myeloma","volume":"93","author":"Terriou","year":"2006","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2011.1404_bib0080","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0095","doi-asserted-by":"crossref","first-page":"576s","DOI":"10.1200\/jco.2010.28.15_suppl.8014","article-title":"Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study","volume":"28","author":"Moreau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2011.1404_bib0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0110","first-page":"116","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1404_bib0120","first-page":"116","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u2265 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs. fixed-duration regimens","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0125","doi-asserted-by":"crossref","first-page":"576s","DOI":"10.1200\/jco.2010.28.15_suppl.8018","article-title":"Lenalidomide maintenance after transplantation for myeloma","volume":"28","author":"Attal","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0130","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1404_bib0135","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1404_bib0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2141.2010.08416.x","article-title":"Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients","volume":"152","author":"Guglielmelli","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2011.1404_bib0145","first-page":"116","article-title":"Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma, IFM 2009-02","author":"Leleu","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0150","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2011.1404_bib0155","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1404_bib0160","first-page":"114","article-title":"RBC transfusion independence and safety profile of lenalidomide 5 or 10mg in pts with low-or Int-1-risk MDS with del5q: results from a randomized phase III trial (MDS 004)","author":"Fenaux","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0165","doi-asserted-by":"crossref","first-page":"pS38","DOI":"10.1016\/S0145-2126(07)70066-8","article-title":"CO28 cytogenetics response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion","volume":"31","author":"List","year":"2007","journal-title":"Leukemia Research"},{"key":"10.1684\/bdc.2011.1404_bib0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/asheducation-2010.1.314","article-title":"How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes","volume":"2010","author":"Blum","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1684\/bdc.2011.1404_bib0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-009-0036-z","article-title":"Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?","volume":"5","author":"Komrokji","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1684\/bdc.2011.1404_bib0185","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2008-08-175778","article-title":"Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study","volume":"113","author":"Ades","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0190","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1200\/JCO.2010.30.3339","article-title":"Dose escalation of lenalidomide in relapsed or refractory acute leukemias","volume":"28","author":"Blum","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2008.01171.x","article-title":"Update on therapeutic options in Waldenstrom macroglobulinemia","volume":"82","author":"Leleu","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1684\/bdc.2011.1404_bib0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1404_bib0205","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1404_bib0210","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.V114.22.1714.1714","article-title":"Biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma","volume":"114","author":"Fowler","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0215","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood.V114.22.1679.1679","article-title":"R2:preliminary results of a phase II study of lenalidomide and rituximab un relapsed\/refractory indolent non-hodgkin's lymphoma (NHL)","volume":"114","author":"Dutia","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0220","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0225","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3109\/10428194.2010.497886","article-title":"Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma","volume":"51","author":"Ivanov","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1684\/bdc.2011.1404_bib0230","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00277-010-1107-x","article-title":"ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation","volume":"90","author":"Tempescul","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1684\/bdc.2011.1404_bib0235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/10428190903350405","article-title":"Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia","volume":"51","author":"Awan","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1684\/bdc.2011.1404_bib0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajh.21892","article-title":"International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens","volume":"86","author":"Thapaliya","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1684\/bdc.2011.1404_bib0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0250","first-page":"1027","article-title":"Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study","volume":"91","author":"Abgrall","year":"2006","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2011.1404_bib0255","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1404_bib0260","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1404_bib0265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","article-title":"Phase1\/-2 study of pomalidomide in myelofibrosis","volume":"85","author":"Mesa","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1684\/bdc.2011.1404_bib0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bmt.1704033","article-title":"Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease","volume":"32","author":"Kulkarni","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1684\/bdc.2011.1404_bib0275","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","article-title":"Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement","volume":"25","author":"Dimopoulos","year":"2011","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2011.1404_bib0280","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/cncr.23336","article-title":"Thromboembolic events with lenalidomide-based therapy for multiple myeloma","volume":"112","author":"Menon","year":"2008","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1404_bib0285","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T23:58:36Z","timestamp":1721606316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0007455115305968"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1404","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}